- Home
- HLI vs MRNA Comparison
HLI vs MRNA Comparison
Compare HLI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HLI | MRNA |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 9.3B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HLI | MRNA |
|---|---|---|
| Price | $177.21 | $27.97 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 13 |
| Target Price | ★ $205.38 | $33.91 |
| AVG Volume (30 Days) | 354.0K | ★ 9.9M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 26.59 | N/A |
| EPS | ★ 6.19 | N/A |
| Revenue | ★ $2,565,361,000.00 | $2,232,000,000.00 |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $13.29 | $0.77 |
| P/E Ratio | $28.62 | ★ N/A |
| Revenue Growth | ★ 21.00 | N/A |
| 52 Week Low | $137.99 | $22.28 |
| 52 Week High | $211.78 | $48.92 |
Technical Indicators
Market Signals| Indicator | HLI | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 61.45 |
| Support Level | $171.77 | $23.92 |
| Resistance Level | $181.75 | $26.00 |
| Average True Range (ATR) | 3.74 | 1.28 |
| MACD | 1.18 | 0.42 |
| Stochastic Oscillator | 63.69 | 99.91 |
Price Performance
Historical ComparisonAbout HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.